Cargando…

Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection

Humoral immunity after SARS-CoV-2 immunization or natural infection is thought to be evanescent. In our study, we aimed to longitudinally characterize the kinetics of antibody titers after dual BNT162b2 immunization or wild-type infection. Vaccinated and recovered individuals displayed distinct anti...

Descripción completa

Detalles Bibliográficos
Autores principales: Lagousi, Theano, Routsias, John, Mavrouli, Maria, Papadatou, Ioanna, Geropeppa, Maria, Spoulou, Vana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416143/
https://www.ncbi.nlm.nih.gov/pubmed/36016097
http://dx.doi.org/10.3390/vaccines10081210
_version_ 1784776407950295040
author Lagousi, Theano
Routsias, John
Mavrouli, Maria
Papadatou, Ioanna
Geropeppa, Maria
Spoulou, Vana
author_facet Lagousi, Theano
Routsias, John
Mavrouli, Maria
Papadatou, Ioanna
Geropeppa, Maria
Spoulou, Vana
author_sort Lagousi, Theano
collection PubMed
description Humoral immunity after SARS-CoV-2 immunization or natural infection is thought to be evanescent. In our study, we aimed to longitudinally characterize the kinetics of antibody titers after dual BNT162b2 immunization or wild-type infection. Vaccinated and recovered individuals displayed distinct antibody kinetics, as convalescents had detectable RBD-, S1-specific, and neutralizing IgG antibody titers two weeks post-infection that gradually increased longitudinally, while RBD-, S1-specific, and neutralizing IgG were detected in vaccinees after the first dose, increased significantly 3 weeks post the second dose and decreased significantly 4–5 months thereafter. Neutralizing IgG was significantly higher initially in convalescent individuals; however, vaccines displayed significantly higher neutralizing antibodies 4–5 months post the second dose. In both groups, there was a strong negative association between elapsed time and antibody levels. The avidity of anti-RBD antibody titers increased significantly in patients longitudinally, while in vaccinees initially increased, with subsequent decrease, remaining however higher than antibody avidity of recovered individuals at all time-points. Anti-RBD antibodies were strongly correlated with neutralizing and anti-S1 antibodies in both groups at all time-points. This study facilitates our further understanding of immune response to SARS-CoV-2 and vaccines.
format Online
Article
Text
id pubmed-9416143
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94161432022-08-27 Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection Lagousi, Theano Routsias, John Mavrouli, Maria Papadatou, Ioanna Geropeppa, Maria Spoulou, Vana Vaccines (Basel) Brief Report Humoral immunity after SARS-CoV-2 immunization or natural infection is thought to be evanescent. In our study, we aimed to longitudinally characterize the kinetics of antibody titers after dual BNT162b2 immunization or wild-type infection. Vaccinated and recovered individuals displayed distinct antibody kinetics, as convalescents had detectable RBD-, S1-specific, and neutralizing IgG antibody titers two weeks post-infection that gradually increased longitudinally, while RBD-, S1-specific, and neutralizing IgG were detected in vaccinees after the first dose, increased significantly 3 weeks post the second dose and decreased significantly 4–5 months thereafter. Neutralizing IgG was significantly higher initially in convalescent individuals; however, vaccines displayed significantly higher neutralizing antibodies 4–5 months post the second dose. In both groups, there was a strong negative association between elapsed time and antibody levels. The avidity of anti-RBD antibody titers increased significantly in patients longitudinally, while in vaccinees initially increased, with subsequent decrease, remaining however higher than antibody avidity of recovered individuals at all time-points. Anti-RBD antibodies were strongly correlated with neutralizing and anti-S1 antibodies in both groups at all time-points. This study facilitates our further understanding of immune response to SARS-CoV-2 and vaccines. MDPI 2022-07-29 /pmc/articles/PMC9416143/ /pubmed/36016097 http://dx.doi.org/10.3390/vaccines10081210 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Brief Report
Lagousi, Theano
Routsias, John
Mavrouli, Maria
Papadatou, Ioanna
Geropeppa, Maria
Spoulou, Vana
Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection
title Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection
title_full Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection
title_fullStr Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection
title_full_unstemmed Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection
title_short Comparative Characterization of Human Antibody Response Induced by BNT162b2 Vaccination vs. SARS-CoV-2 Wild-Type Infection
title_sort comparative characterization of human antibody response induced by bnt162b2 vaccination vs. sars-cov-2 wild-type infection
topic Brief Report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9416143/
https://www.ncbi.nlm.nih.gov/pubmed/36016097
http://dx.doi.org/10.3390/vaccines10081210
work_keys_str_mv AT lagousitheano comparativecharacterizationofhumanantibodyresponseinducedbybnt162b2vaccinationvssarscov2wildtypeinfection
AT routsiasjohn comparativecharacterizationofhumanantibodyresponseinducedbybnt162b2vaccinationvssarscov2wildtypeinfection
AT mavroulimaria comparativecharacterizationofhumanantibodyresponseinducedbybnt162b2vaccinationvssarscov2wildtypeinfection
AT papadatouioanna comparativecharacterizationofhumanantibodyresponseinducedbybnt162b2vaccinationvssarscov2wildtypeinfection
AT geropeppamaria comparativecharacterizationofhumanantibodyresponseinducedbybnt162b2vaccinationvssarscov2wildtypeinfection
AT spoulouvana comparativecharacterizationofhumanantibodyresponseinducedbybnt162b2vaccinationvssarscov2wildtypeinfection